Fig. 1

KIAA1522 expression predicts platinum-based therapeutic effectiveness in lung adenocarcinomas. a Forest plot shows the hazard ratio with 95% confidence interval of each tested protein. The hazard ratios are estimated by univariate cox analyses in all NSCLC patients (blue) or the patients receiving post-surgery platinum-based chemotherapy (red). The proteins were ranked by the p-values in the chemotherapy group. b-f Immunohistochemical analyses of KIAA1522 expression in tissue samples from NSCLC patients. b Representative images of KIAA1522 immunohistochemical staining in NSCLC specimens and non-tumoral normal lung tissues. Bar = 100 μm. c Paired comparisons of KIAA1522 expression in non-tumoral and tumor samples in either lung adenocarcinomas (ADC) or squamous cell carcinomas (SCC), paired t-test, ****P < 0.0001. d In ADC and SCC patients, multivariate cox analyses of prognostic values of KIAA1522 levels excluding age, sex, stage, grade and post-surgical chemotherapy. e Kaplan–Meier curves show the overall survival of NSCLC patients expressing high/low levels of KIAA1522 protein with or without platinum-based post-surgical adjuvant chemotherapy. f Comparisons of prognostic effects of platinum-based chemotherapy in KIAA1522 high expression or low expression groups respectively